406 results on '"Raggi, D"'
Search Results
2. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆
3. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
4. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial
5. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma
6. 27P Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase II ARCADIA trial
7. 26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)
8. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
9. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes
10. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study
11. Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database
12. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
13. OP20 Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: Final results from the PURE-01 study
14. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes
15. 2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
16. 1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
17. 695P Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
18. Re: MultiparametricMagnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
19. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
20. A0901 - First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)
21. A0875 - Comprehensive Genomic Profiling (CGP) of clinical T2-4N0M0 Muscle-Invasive Bladder Cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before Radical Cystectomy (RC)
22. A0874 - The role of androgen response pathway in association with tumor biology and response to neoadjuvant Immune-Checkpoint Inhibitors (ICI) in Muscle-Invasive urothelial Bladder Carcinoma (MIBC)
23. A0625 - The effect of metabolic syndrome on long-term renal function after partial nephrectomy
24. A0610 - Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET
25. A0487 - Standardized assessment of Perioperative outcomes of robot-assisted radical cystectomy assessed using the EAU guidelines for collecting and reporting complications
26. A0365 - Cancer control rates in adequate versus inadequate treatment with adjuvant immunotherapy instillations with BCG
27. A0360 - Defining intermediate-risk non-muscle invasive bladder cancer: A comparative study of EAU and IBCG criteria
28. P214 - Impact of neoadjuvant chemo-immunotherapy on intra and post operative outcomes in patients with bladder cancer treated with radical cystectomy and pelvic lymph node dissection: Prospective surgical assessment from the NURE-Combo Trial
29. Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma
30. IMPACT OF DISEASE RESPONSIVENESS PRE-TRANSPLANT ON SURVIVAL IN ADULT MALES WITH GERM CELL TUMORS (GCT). EARLY RESULTS AND IMPLICATIONS FOR THE SALVAGE TREATMENT STRATEGY: PH-O124
31. 2370P Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
32. 2368P Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
33. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle -invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study
34. 153P Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
35. SC127 - Three year-survival outcomes after neoadjuvant pembrolizumab and radical cystectomy: final results from the pure-01 study
36. SC91 - Impact of 68Ga-PSMA PET/CT and metastasis-directed therapy on clinical recurrence in patients with biochemical recurrence after radical prostatectomy. results from a single center series
37. SC54 - Imaging intensity after surgery for clear cell renal cell carcinoma
38. SC53 - When to de-intensify oncologic surveillance scheme for non-clear cell renal cell carcinoma
39. SC52 - The added value of histological subtype in the prediction of oncologic outcomes in patients with non-metastatic papillary renal cell carcinoma
40. SC33 - The impact of variant histology on the probability of lymph node involvement at imaging: CT scan vs FDG PET
41. SC34 - The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy
42. SC12 - The impact of histological variants on the performance characteristics of 68Ga-PSMA PET/CT in the primary and recurrent setting
43. SC269 - When node-positive prostate cancer should be considered a systemic disease? assessing the prognostic role of preoperative 68Ga-PSMA PET/ CT results in patients with lymph node invasion at final pathology
44. SC248 - Oncologic outcomes in patients diagnosed with PT3A non-metastatic renal cell cancer according to renal vein thrombus or fat invasion
45. SC247 - Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy
46. SC245 - Application of the keynote-564 trial results to real life population: which patients with advanced kidney cancer should receive adjuvant pembrolizumab
47. SC234 - Optimizing timing and indications for 68Ga-PSMA PET/CT in patients with biochemical recurrent prostate cancer after radical prostatectomy
48. SC228 - How to maximize the diagnostic rate of endoscopic biopsy during flexible ureteroscopy for upper tract urothelial carcinoma
49. SC201 - When is neoadjuvant androgen deprivation therapy beneficial for highly aggressive prostate cancer before radical prostatectomy? implications for multi-modal tailored approaches and trials design
50. 1738P Three-year follow-up update and survival outcomes of the PURE-01 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.